---
figid: PMC3493824__nihms412260f1
figlink: /pmc/articles/PMC3493824/figure/F1/
number: Figure 1
caption: In addition to cytokine neutralization (IL-1, IL-6, TNFα, IL-12/23), direct
  cellular targeting is being used successfully in autoimmune disease. Rituximab targets
  B-cell surface marker CD20 resulting in B cell depletion, whereas belimumab targets
  the BLyS pathway that ultimately affects B cell maturation and survival. With respect
  to T cell effector function, abatacept blocks CD28 co-stimulation with CD80/86 after
  antigen presentation and T cell receptor engagement. In contrast, alefacept (CD2
  antagonism with a LFA-3 fusion protein) and efalizumab (LFA-1/ICAM-1 inhibition)
  decrease T cell activation or migration, respectively.
pmcid: PMC3493824
papertitle: Cellular Targeting in Autoimmunity.
reftext: Jennifer L. Rogers, et al. Curr Allergy Asthma Rep. ;12(6):495-510.
pmc_ranked_result_index: '92636'
pathway_score: 0.8031987
filename: nihms412260f1.jpg
figtitle: Cellular Targeting in Autoimmunity
year: ''
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3493824__nihms412260f1.html
  '@type': Dataset
  description: In addition to cytokine neutralization (IL-1, IL-6, TNFα, IL-12/23),
    direct cellular targeting is being used successfully in autoimmune disease. Rituximab
    targets B-cell surface marker CD20 resulting in B cell depletion, whereas belimumab
    targets the BLyS pathway that ultimately affects B cell maturation and survival.
    With respect to T cell effector function, abatacept blocks CD28 co-stimulation
    with CD80/86 after antigen presentation and T cell receptor engagement. In contrast,
    alefacept (CD2 antagonism with a LFA-3 fusion protein) and efalizumab (LFA-1/ICAM-1
    inhibition) decrease T cell activation or migration, respectively.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CD2
  - IL12A
  - IL6
  - IL23A
  - TNFSF13B
  - TNF
  - IL12B
  - ICAM1
  - IL1A
  - CD28
  - IL1B
  - CD4
  - MS4A1
genes:
- word: CD2
  symbol: CD2
  source: hgnc_symbol
  hgnc_symbol: CD2
  entrez: '914'
- word: IL-12/23
  symbol: IL12
  source: bioentities_symbol
  hgnc_symbol: IL12A
  entrez: '3592'
- word: IL-6
  symbol: IL-6
  source: hgnc_alias_symbol
  hgnc_symbol: IL6
  entrez: '3569'
- word: IL-12/23
  symbol: IL-23
  source: hgnc_alias_symbol
  hgnc_symbol: IL23A
  entrez: '51561'
- word: BLYS/BAFF
  symbol: BAFF
  source: hgnc_alias_symbol
  hgnc_symbol: TNFSF13B
  entrez: '10673'
- word: TNF-a
  symbol: TNF-alpha
  source: hgnc_alias_symbol
  hgnc_symbol: TNF
  entrez: '7124'
- word: IL-12/23
  symbol: IL12
  source: bioentities_symbol
  hgnc_symbol: IL12B
  entrez: '3593'
- word: BLYS/BAFF
  symbol: BLYS
  source: hgnc_alias_symbol
  hgnc_symbol: TNFSF13B
  entrez: '10673'
- word: LFA-1/ICAM-1
  symbol: ICAM1
  source: hgnc_symbol
  hgnc_symbol: ICAM1
  entrez: '3383'
- word: IL-1
  symbol: IL1
  source: bioentities_symbol
  hgnc_symbol: IL1A
  entrez: '3552'
- word: CD28
  symbol: CD28
  source: hgnc_symbol
  hgnc_symbol: CD28
  entrez: '940'
- word: IL-1
  symbol: IL1
  source: bioentities_symbol
  hgnc_symbol: IL1B
  entrez: '3553'
- word: CD4+
  symbol: CD4
  source: hgnc_symbol
  hgnc_symbol: CD4
  entrez: '920'
- word: CD20
  symbol: CD20
  source: hgnc_prev_symbol
  hgnc_symbol: MS4A1
  entrez: '931'
chemicals: []
diseases: []
---
